Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-04-22
    E.g., 2018-04-22



50481 items
4:22 PM, Apr 20, 2018  |  BC Extra | Company News

Vertex to meet with NHS England to discuss Orkambi

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said it expects to meet with NHS England next week to discuss Orkambi ivacaftor/lumacaftor following its receipt of a letter from the U.K. Department of Health urging the company to proceed...
4:19 PM, Apr 20, 2018  |  BC Extra | Company News

Dicerna, Alnylam settle RNAi dispute

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) gained $1.82 (18%) to $12.01 Friday after the company said it had resolved all litigation with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) regarding RNAi-based treatments for primary hyperoxaluria, with neither company admitting wrongdoing. In...
3:15 PM, Apr 20, 2018  |  BC Extra | Politics & Policy

Gottlieb unveils guidance for opioid dependence treatments

As part of an effort to address the opioid abuse epidemic, FDA released draft guidance for the development and clinical trial design of sustained-release depot buprenorphine products -- modified-release medication-assisted treatments (MATs) for injection or...
2:49 PM, Apr 20, 2018  |  BC Extra | Company News

Management tracks: Nordic Nanovector, Ra

Blood cancer company Nordic Nanovector ASA (OSE:NANO) appointed CFO Tone Kvåle as interim CEO. Complement-mediated disease company Ra Pharmaceuticals Inc. (NASDAQ:RARX) hired John King as chief commercial officer. King was VP of the U.S. neurology business...
2:21 PM, Apr 20, 2018  |  BC Extra | Company News

Brazil nixes Soliris patent, says more could follow

A Brazilian court unanimously ruled Friday to remove patent protection for Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), opening the door for production of biosimilar versions in the country. In a statement, Brazil’s Attorney General...
12:52 PM, Apr 20, 2018  |  BC Extra | Company News

UCB buys rights to seizure candidate

UCB S.A. (Euronext:UCB) acquired rights to intranasal midazolam (USL261) from the Proximagen LLC subsidiary of Acova Inc. (Plymouth, Minn.). Proximagen will receive $150 million up front and is eligible for $220 million in milestones. The...
11:42 AM, Apr 20, 2018  |  BC Extra | Company News

Biogen, Ionis expanding antisense deal

Biogen Inc. (NASDAQ:BIIB) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) expanded their existing partnership to develop antisense therapies for a range of disease areas including dementia and neurological disease in a 10-year collaboration. Ionis is to receive $1...
11:39 AM, Apr 20, 2018  |  BC Extra | Company News

Shire mulling Takeda's latest bid

Shire plc (LSE:SHP; NASDAQ:SHPG) said Friday its board is considering a fourth takeover bid from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502). On Thursday, Shire said it had rejected Takeda's third offer (see BioCentury Extra, April 19). Takeda's...
7:45 AM, Apr 20, 2018  |  BC Extra | Financial News

Days after first drug approval, Rigel raises $62.4M

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) raised $62.4 million through the sale of 16 million shares at $3.90 in a follow-on underwritten by Jefferies, Piper Jaffray, BMO Capital Markets and H.C. Wainwright. The price is a tiny premium...
5:03 PM, Apr 19, 2018  |  BC Extra | Company News

Shire rejects third Takeda bid, as Allergan drops out

Shire plc (LSE:SHP; NASDAQ:SHPG) said Thursday its board has unanimously rejected three separate takeout offers from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), culminating at the most recent bid valued at £44 billion ($62.7 billion) in which...